Chardan Capital Increases Dyne Therapeutics (NASDAQ:DYN) Price Target to $31.00

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) had its price objective raised by analysts at Chardan Capital from $20.00 to $31.00 in a research report issued to clients and investors on Friday, Stock Target Advisor reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s target price would indicate a potential upside […]

Leave a Reply

Your email address will not be published.

Previous post Maxeon Solar Technologies (NASDAQ:MAXN) Rating Lowered to Sell at UBS Group
Next post Viavi Solutions (NASDAQ:VIAV) Cut to Hold at StockNews.com